Continue to Activity
Please allow pop-ups for this page

The Bad Ad Program and Prescription Drug Promotion

About this site:

This activity is supported by the US Food and Drug Administration (FDA) through a contract from the US Office of Personnel Management, and FDA's privacy policies apply while you are on this site.

Users not completing the course for CME/CE credit may print a Certificate of Completion at the end of the course.

CME/CE Released:10/15/2013; Valid for credit through 10/15/2014

Credits Available:

  • Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™
  • Nurses – 1.00 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
  • Pharmacists – 1.00 Knowledge-based ACPE (TBD CEUs)
  • Nurse Practitioners – 1.00 AANP Contact Hours
  • Physician Assistants – 1.00 AAPA hour(s) of Category I Credit

Target Audience:

This activity is intended for current and future physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other healthcare professionals who prescribe medication or make selection decisions about the use of prescription drugs for patients.

Goal:

The goal of this activity is to educate healthcare professionals and students about the role they can play in helping the FDA ensure that prescription drug advertising and promotion is truthful and not misleading.

Learning Objectives:

Upon completion of this activity, participants will be able to:

  1. Identify the role that FDA, OPDP and HCPs play in regulating prescription drug promotion and advertising
  2. Describe the most common regulatory issues raised by prescription drug promotion
  3. Recognize false or misleading prescription drug promotion

Faculty and Disclosures:

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

This activity does not include discussion of off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

This activity does not include discussion of investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty:

Robert Dean, MBA (contributor)

Division Director, FDA Office of Prescription Drug Promotion

Disclosure: Robert Dean, MBA has disclosed no relevant financial relationships.

Michael Sauers, MPP (contributor / presenter)

Deputy Division Director, FDA Office of Prescription Drug Promotion

Disclosure: Michael Sauers, MPP, has disclosed no relevant financial relationships.

LT Jessica Cleck Derenick, PhD (contributor)

Team Leader, FDA Office of Prescription Drug Promotion

Disclosure: LT Jessica Cleck Derenick, PhD has disclosed no relevant financial relationships.

Meeta Patel, PharmD (contributor)

Regulatory Review Officer, FDA Office of Prescription Drug Promotion

Disclosure: Meeta Patel, PharmD has disclosed no relevant financial relationships.

Michelle Safarik, MSPAS, PA-C (contributor)

Regulatory Review Officer, FDA Office of Prescription Drug Promotion

Disclosure: Michelle Safarik, MSPAS, PA-C has disclosed no relevant financial relationships.

Linda J. Demaine, JD, PhD (contributor / presenter)

Expert Consultant: Psychology of Influence

Disclosure: Linda J. Demaine, JD, PhD has disclosed no relevant financial relationships.

LT Christine Corser, PharmD (presenter)

Regulatory Review Officer, FDA Office of Prescription Drug Promotion

Disclosure: LT Christine Corser, PharmD, receives income in an amount equal to or greater than $250 from the Supervalu Inc. pharmacy.

LT Jessica Fox, PharmD (presenter)

Regulatory Review Officer, FDA Office of Prescription Drug Promotion

Disclosure: LT Jessica Fox, PharmD, has disclosed no relevant financial relationships.

LCDR Melinda McLawhorn, PharmD, BCPS (presenter)

Regulatory Review Officer, FDA Office of Prescription Drug Promotion

Disclosure: LCDR Melinda McLawhorn, PharmD, BCPS, has disclosed no relevant financial relationships.

Twyla Thompson, PharmD (presenter)

Team Leader, FDA Office of Prescription Drug Promotion

Disclosure: Twyla Thompson, PharmD, has disclosed no relevant financial relationships.

Janet Woodcock, MD (Presenter)

Director, Center for Drug Evaluation and Research, Food and Drug Administration

Disclosure: Janet Woodcock, MD has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD
CME Clinical Director, Medscape, LLC

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

Laurie E. Scudder, DNP, NP
Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.